Most fusion companies sell a future. SHINE Technologies ships product.
The Wisconsin-based firm launched its Ilumira lutetium-177 offering in June 2024, delivering medical isotopes used in targeted cancer therapy to customers across 19 countries. By June 2025, the company reported maintaining better than 95% on-time, in-full delivery—the kind of operational metric that matters more to hospital procurement teams than any breakthrough in fusion energy's theoretical potential. When the European Medicines Agency issued a positive opinion on Ilumira as a radiopharmaceutical precursor this past January, it opened access to additional markets and validated a business model most fusion watchers didn't see coming.
This matters because SHINE represents something genuinely unusual in an industry defined by long timelines and deferred revenue: actual commercial operations before achieving net energy gain. While Commonwealth Fusion Systems was raising $900 million in late 2025 to target fusion experiments around 2027, SHINE was already operating commercial facilities in Janesville, producing medical isotopes and running neutron testing services for defense contractors. Different game entirely.
The Medical Isotope Crisis Nobody Sees Coming
The nuclear medicine supply chain runs on borrowed time—borrowed from reactors, mostly, that were built when Kennedy was in office.
Technetium-99m powers more than 80% of nuclear medicine diagnostic scans globally. That's roughly 40,000 procedures daily in the United States alone, tracking everything from bone tumors to cardiac blood flow. Nearly all of it comes from aging research reactors scattered across Europe, Australia, and South Africa. When the High Flux Reactor at Petten, Netherlands went offline for maintenance last October and November, hospitals across Europe canceled procedures. Patients waited. Doctors improvised.
The OECD Nuclear Energy Agency doesn't mince words in its 2023-2027 security-of-supply assessment: urgent policy action required. Most molybdenum-99 (which decays to Tc-99m) still depends on highly enriched uranium targets in reactors built decades ago. The industry has been racing to replace HFR Petten before its planned closure, with the PALLAS replacement reactor receiving construction approval in July 2025. Operations target sometime around 2030. Perhaps.
SHINE saw the gap and drove a truck through it.
The company's Chrysalis facility, under construction in Janesville, is designed to produce up to 20 million patient doses of Mo-99 annually when it comes online in early 2027. That represents more than one-third of global demand, according to company projections. Then on January 2 this year, SHINE acquired Lantheus' SPECT business, including TechneLite Tc-99m generator manufacturing operations in North Billerica, Massachusetts—vertically integrating the entire supply chain from isotope production through distribution. One company, one supply line, no aging European reactors required.
The economics just shifted in SHINE's favor, too. Starting January 1, 2026, the Centers for Medicare & Medicaid Services implemented a $10 add-on payment per dose for Tc-99m derived from domestically produced, non-HEU Mo-99—provided at least 50% of the material is domestic. That policy change, combined with $114 million in DOE and National Nuclear Security Administration support since 2010 (including an additional $32 million awarded last July), positions SHINE to compete against subsidized foreign production on something closer to even footing.
Fusion's Neutron Problem Is SHINE's Business Model
Greg Piefer, SHINE's founder and CEO, argues that "neutrons can be more valuable than the energy" in specific applications. It's a counterintuitive pitch in an industry obsessed with gigawatt-scale power plants. But the numbers back him up.
SHINE operates multiple fusion neutron generators as irradiation drivers. Unlike tokamaks or stellarators designed to contain plasma long enough for net energy gain, SHINE's systems optimize for neutron flux—maximizing particle output, not energy return. The company's Cassiopeia facility, opened in 2024, uses this approach to produce up to 100,000 doses annually of no-carrier-added lutetium-177, expandable to 200,000 doses. Chrysalis will deploy the same neutron-driven process for Mo-99.
The company's FLARE facility takes the neutron-first strategy in another direction entirely. Launched in 2023 and marketed as the "brightest steady-state 14-MeV neutron fusion source," generating up to 50 trillion fusions per second, FLARE provides radiation-effects testing for defense and space electronics. The radiation-hardened electronics market sits around $1.77 billion in 2025, projected to reach $2.30 billion by 2030—driven by satellite constellations and defense systems that need survivability testing before launch. SHINE rents out neutron exposure time the way cloud providers rent compute cycles.
Phoenix Neutron Imaging Center, another SHINE subsidiary operating in Fitchburg, Wisconsin, achieved ASTM Category I neutron radiography using accelerator-based systems. That's historically been reactor domain. The facility holds a U.S. Army contract for munitions inspection, citing 99% uptime over 39 weeks in one operational period. Not fusion energy, but profitable.
Three different revenue streams, all derived from fusion neutrons, none waiting for fusion energy to become commercially viable. The phased approach de-risks capital deployment in ways familiar to any venture investor, even if the underlying physics remains exotic.
The Nuclear Waste Gambit
SHINE's third phase ventures into territory that makes medical isotopes look straightforward by comparison.
On March 1, 2024, the company signed a memorandum of understanding with Orano USA to co-develop a pilot plant for recycling used nuclear fuel at approximately 100 metric tons per year capacity. It's a big swing. The United States has roughly 90,000 metric tons of used fuel sitting in dry casks at reactor sites—a stable feedstock with no current domestic reprocessing pathway. France's Orano operates the La Hague facility at 1,700 metric tons per year, recovering uranium and plutonium for reuse.
SHINE's twist involves using fusion neutrons to transmute long-lived radioactive waste into shorter-lived isotopes, potentially solving one of nuclear power's thorniest problems while extracting valuable isotopes like strontium-90 for niche applications. Local Wisconsin media reported SHINE partnered with Zeno Power to sell recycled Sr-90, though details remain limited and the companies haven't elaborated publicly.
The technical complexity here multiplies fast. Separating isotopes, managing actinides, demonstrating transmutation at scale, navigating safeguards and public acceptance—each challenge compounds the others. Piefer positions it as a necessary step before attempting utility-scale fusion power, arguing the company needs operational experience managing fusion systems in high-consequence environments before taking on the really hard stuff.
It's ambitious. Perhaps overly so. But the staged approach means SHINE doesn't need the recycling business to succeed tomorrow; Mo-99 revenue and neutron testing contracts fund development work. That contrasts sharply with fusion energy ventures that must raise billions before generating a dollar of revenue, then hope the physics cooperates.
What This Means for Fusion's Next Decade
Private fusion funding reached approximately $9.7 billion by mid-2025, according to the Fusion Industry Association. Most of those dollars chase the same prize: demonstrating net energy gain, then scaling to pilot plants, then building commercial reactors sometime in the 2030s or 2040s. Maybe. The Department of Energy's 2024 Fusion Energy Strategy aligns public-private pathways toward pilot plants by the 2030s, supporting efforts through programs like the Milestone-Based Fusion Development Program.
SHINE demonstrates an alternative path—one that pays rent while you perfect the technology.
The company raised $70 million in October 2023, led by Baillie Gifford and Fidelity, to "accelerate commercialization of near-term applications of fusion technology." Cumulative funding across private and public sources sits around $676 million over 19 rounds, according to industry trackers. That's significant but nowhere near the billion-dollar rounds Commonwealth Fusion or Helion command. SHINE hasn't needed those rounds, at least not yet.
The regulatory environment is evolving to accommodate this divergence between fusion-for-neutrons and fusion-for-energy. In 2023, the Nuclear Regulatory Commission voted to regulate fusion under 10 CFR Part 30 as byproduct material, not under Part 50's fission reactor framework—a crucial distinction that spares fusion startups from decades of prescriptive safety requirements. The NRC published proposed fusion-specific rules and guidance on February 26, 2026, projected for finalization by October. That lighter-touch regulatory approach could accelerate non-energy fusion applications while the industry works through tritium breeding, materials science, and the brutal economics of power generation.
Competition is coming, though. Canada's Darlington nuclear station now produces Mo-99 through neutron activation in its CANDU power reactors, with capacity ramping and a May 2025 license amendment adding Lu-177 and Y-90 production. Europe's PALLAS reactor aims for around 2030 operations to replace Petten. Multiple suppliers entering the market should stabilize global isotope supply by the late 2020s, which will test SHINE's economics against subsidized foreign competition—precisely the challenge that forced NorthStar Medical to exit U.S. Mo-99 production in 2023.
SHINE's competitive moat rests on vertical integration and domestic policy support, not just superior technology. The CMS reimbursement add-on, DOE cost-sharing, and the SPECT acquisition create structural advantages that pure-play foreign producers can't easily replicate. Whether that's enough remains an open question. Ask again in 2028.
The Longer Game
Piefer's four-phase roadmap places fusion energy last, not first. Neutron testing and imaging (phase one) operates commercially today. Medical isotopes (phase two) ship this year, with Mo-99 production starting 2027. Used fuel recycling (phase three) targets the early 2030s. Only then does SHINE plan to tackle commercial fusion power generation (phase four)—if at all.
It's a founder's bet that markets will value what fusion can do today more than what it might do tomorrow. That cancer patients need Lu-177 now, that hospitals face Mo-99 shortages now, that defense contractors need radiation testing now. Energy abundance can wait its turn.
Perhaps this pragmatism points toward how deep tech actually scales in the real world: not through singular moonshots but through stacked revenue streams that fund longer-term bets. Or perhaps SHINE simply found the one application where fusion's notorious difficulty doesn't matter, because the alternative is depending on reactors built when Eisenhower was president.
Either way, the fusion industry can debate timelines to net gain all it wants. SHINE already delivers commercially valuable neutrons, ships product to 19 countries, and posts operational metrics that would bore a hospital supply chain manager to tears—which is precisely the point.
That's less inspirational than limitless clean energy, maybe. But it pays the bills while everyone else waits for their reactors to work.
